Latest news with #KeplerCapital
Business Insider
2 days ago
- Business
- Business Insider
Kepler Capital Reaffirms Their Buy Rating on Neste Corporation (0O46)
Kepler Capital analyst Pablo Cuadrado maintained a Buy rating on Neste Corporation on July 24 and set a price target of €13.80. The company's shares closed last Friday at €14.61. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Cuadrado is a 4-star analyst with an average return of 7.6% and a 56.55% success rate. Cuadrado covers the Industrials sector, focusing on stocks such as Bureau Veritas, Construcciones y Auxiliar de Ferrocarriles, and SGS SA. In addition to Kepler Capital , Neste Corporation also received a Buy from Goldman Sachs's Michele Della Vigna in a report issued on July 25. However, on the same day, Banco Santander downgraded Neste Corporation (LSE: 0O46) to a Hold.
Yahoo
2 days ago
- Business
- Yahoo
Kepler Capital Maintained a Buy Rating on Genfit (GNFT)
Genfit S.A. (NASDAQ:GNFT) is one of the . On July 8, Justine Telliez from Kepler Capital maintained a Buy rating on Genfit S.A. (NASDAQ:GNFT) with a price target of €8.40. The rating comes after the company released its mid-year update on its liquidity contract with Credit Industriel et Commercial. The company noted that as of June 30, 2025, there were 201,000 shares in the liquidity account along with €398,484.67 in cash in liquidity. Moreover, the company also released details about its trading activity, which shows 1,412,901 shares were bought, 1,419,301 shares were sold, with the number of buy and sell trades standing at 2,673 and 1,894, respectively. A biotechnologist in a laboratory wearing a lab coat, preparing samples for a clinical trial. Genfit S.A. (NASDAQ:GNFT) is a French biopharmaceutical company that develops treatments and diagnostic tools for rare and serious liver diseases. While we acknowledge the potential of GNFT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
2 days ago
- Business
- Yahoo
Kepler Capital Remains Bullish on Novo Nordisk A/S (NVO)
Novo Nordisk A/S (NYSE:NVO) is one of the top low volatility healthcare stocks to buy now. In a report released on July 17, David Evans from Kepler Capital maintained a Buy rating on Novo Nordisk A/S (NYSE:NVO) with a price target of DKK630.00. An elderly couple receiving insulin from a pharmacist, representing healthcare company's successful pharmaceutical products. Novo Nordisk A/S (NYSE:NVO) reported a 22% growth in operating profit in Danish kroner and 20% at constant exchange rates (CER) to DKK 38.8 billion in the first three months of 2025. Sales in US Operations rose by 20% in Danish kroner and 17% at CER, while sales in International Operations grew by 18% in Danish kroner and 19% at CER in the same period. Novo Nordisk A/S (NYSE:NVO) also experienced a 21% growth in Danish kroner in sales within Diabetes and Obesity care, primarily attributed to the Obesity care growth of 67% in Danish kroner to DKK 18.4 billion and GLP-1 diabetes sales growth of 13% in Danish kroner. Novo Nordisk A/S (NYSE:NVO) is a global healthcare company specializing in diabetes care. It develops, discovers, manufactures, and markets pharmaceutical products. Its operations are divided into two business segments: biopharmaceuticals and diabetes and obesity care. The latter segment covers GLP-1, insulin, and other protein-related products. While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Business Insider
3 days ago
- Business
- Business Insider
ENI S.p.A. (0N9S) Gets a Hold from Kepler Capital
In a report released on July 25, Bertrand Hodee from Kepler Capital maintained a Hold rating on ENI S.p.A., with a price target of €13.00. The company's shares closed last Friday at €14.66. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Hodee covers the Energy sector, focusing on stocks such as TotalEnergies SE, Technip Energies NV, and Equinor ASA. According to TipRanks, Hodee has an average return of 18.7% and a 62.42% success rate on recommended stocks. In addition to Kepler Capital , ENI S.p.A. also received a Hold from UBS's Joshua Stone in a report issued on July 25. However, on the same day, DZ BANK AG maintained a Buy rating on ENI S.p.A. (LSE: 0N9S). Based on ENI S.p.A.'s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of €22.57 billion and a net profit of €1.17 billion. In comparison, last year the company earned a revenue of €22.94 billion and had a net profit of €1.21 billion
Business Insider
3 days ago
- Business
- Business Insider
Valiant Holding (0QPU) Receives a Hold from Kepler Capital
Kepler Capital analyst Nicolas Payen maintained a Hold rating on Valiant Holding on July 25 and set a price target of CHF115.00. The company's shares closed last Friday at CHF129.40. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Payen covers the Financial sector, focusing on stocks such as Barclays, Deutsche Bank AG, and NatWest Group. According to TipRanks, Payen has an average return of 15.5% and a 69.35% success rate on recommended stocks. Currently, the analyst consensus on Valiant Holding is a Hold with an average price target of CHF115.00. Based on Valiant Holding's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of CHF187.62 million and a net profit of CHF32.75 million. In comparison, last year the company earned a revenue of CHF215.53 million and had a net profit of CHF31.74 million
